SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia: a population-based study.

ABSTRACT:

Background

We nested a seroprevalence survey within the TREATS (Tuberculosis Reduction through Expanded Antiretroviral Treatment and Screening) project. We aimed to measure the seroprevalence of SARS-CoV-2 infection and investigate associated risk factors in one community (population ∼27,000) with high prevalence of TB/HIV in Zambia.

Methods

The study design was cross-sectional. A random sample of 3592 individuals aged ≥15 years enrolled in the TREATS TB-prevalence survey were selected for antibody testing. Randomly selected blocks of residence were visited between October 2020 and March 2021. Antibodies against SARS-CoV-2 were detected using Abbott- ARCHITECT SARS-CoV-2 IgG assay.

Results

A total of 3035/3526 (86.1%) individuals had a blood sample taken. Antibody tes

SUBMITTER: Shanaube K 

PROVIDER: S-EPMC8925090 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature